Hologic/$HOLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Ticker
$HOLX
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
7,063
ISIN
US4364401012
Website
Hologic Metrics
BasicAdvanced
$14B
26.76
$2.39
0.55
-
Price and volume
Market cap
$14B
Beta
0.55
52-week high
$84.67
52-week low
$51.90
Average daily volume
3.9M
Financial strength
Current ratio
3.242
Quick ratio
2.289
Long term debt to equity
53.29
Total debt to equity
54.507
Interest coverage (TTM)
7.74%
Profitability
EBITDA (TTM)
1,252.3
Gross margin (TTM)
61.06%
Net profit margin (TTM)
13.83%
Operating margin (TTM)
23.77%
Effective tax rate (TTM)
18.29%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
6.92%
Return on equity (TTM)
11.77%
Valuation
Price to earnings (TTM)
26.763
Price to revenue (TTM)
3.672
Price to book
3.09
Price to tangible book (TTM)
45.01
Price to free cash flow (TTM)
15.24
Free cash flow yield (TTM)
6.56%
Free cash flow per share (TTM)
419.76%
Growth
Revenue change (TTM)
1.66%
Earnings per share change (TTM)
25.36%
3-year revenue growth (CAGR)
-9.27%
10-year revenue growth (CAGR)
4.55%
3-year earnings per share growth (CAGR)
-26.64%
10-year earnings per share growth (CAGR)
19.37%
What the Analysts think about Hologic
Analyst ratings (Buy, Hold, Sell) for Hologic stock.
Bulls say / Bears say
Hologic's adjusted operating margin expanded by 170 basis points to 28.3% in the fiscal fourth quarter, driven by higher revenues and improved operating leverage. (TradingView News)
The company reported a robust free cash flow of $1.14 billion in the trailing twelve months, indicating strong operational efficiency and financial health. (TipRanks)
Hologic's debt-to-equity ratio is low at 0.01, showcasing prudent financial management and a healthy balance sheet. (TipRanks)
Hologic's stock reached a 52-week low of $70.5 amid market shifts, reflecting investor concerns over its performance. (Investing.com)
The company reported a quarterly loss of $17.4 million for the quarter ended March 31, indicating potential financial challenges. (TradingView News)
Analysts at Leerink Partners reduced their Q3 2025 earnings estimates for Hologic, reflecting a bearish outlook on the company's near-term financial performance. (Defense World)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Hologic Financial Performance
Revenues and expenses
Hologic Earnings Performance
Company profitability
Hologic News
AllArticlesVideos

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
Business Wire·3 weeks ago

Hologic reportedly rejects $16B go-private offer from TPG, Blackstone
Proactive Investors·3 weeks ago

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hologic stock?
Hologic (HOLX) has a market cap of $14B as of June 20, 2025.
What is the P/E ratio for Hologic stock?
The price to earnings (P/E) ratio for Hologic (HOLX) stock is 26.76 as of June 20, 2025.
Does Hologic stock pay dividends?
No, Hologic (HOLX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Hologic dividend payment date?
Hologic (HOLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Hologic?
Hologic (HOLX) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.